BENEVICH ERIC 4/A
4/A · NEUROCRINE BIOSCIENCES INC · Filed Jan 16, 2026
Insider Transaction Report
Form 4/AAmended
BENEVICH ERIC
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
[F1][F2]2025-11-28$35.99/sh+12,830$461,752→ 57,723 total - Exercise/Conversion
Incentive Stock Option
[F1][F4]2025-11-28−12,830→ 0 totalExercise: $35.99Exp: 2026-02-05→ Common Stock (12,830 underlying)
Holdings
- 51,753
Common Stock
[F3]
Footnotes (4)
- [F1]This Form 4 is being amended to correct the reporting of the Reporting Persons November 28, 2025 transaction. Due to an administrative error, the original Form 4 inadvertently reported the exercise of 5,970 stock options. The transaction actually consisted of the exercise of 12,830 stock options.
- [F2]Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
- [F3]This line is included solely to report the Reporting Persons corrected beneficial ownership of Common Stock in Column 5 following the November 28, 2025 transactions previously reported in the Form 4 filed on December 2, 2025.
- [F4]The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026.
Signature
/s/ Darin Lippoldt, Attorney-in-Fact|2026-01-16